JMP Securities Maintains Ironwood Pharmaceuticals(IRWD.US) With Buy Rating, Maintains Target Price $14
Ironwood Pharmaceuticals: Stability and Growth Potential Amid Internal Control Improvements
Ironwood Pharmaceuticals | 10-K: FY2024 Annual Report
Express News | Ironwood Pharmaceuticals Receives Letter Of Nasdaq Non-Compliance Notification Regarding Late 2024 Form 10-K Filing
Hospital Stocks Are Ready to Rebound, Deutsche Bank Says
Proposed Medicaid Cuts Would Devastate Local Economies: Report -- Barrons.com
The tariff war between the US and Europe is escalating, and Trump's 'tariff big stick' is making the pharmaceutical industry tremble.
Pharmaceutical companies are urging the Trump administration and EU officials to exclude Medical products from the escalation of the trade war.
New York Manufacturing Hits Low, Inflation Fears Rise
Craig-Hallum Sticks to Its Buy Rating for Ironwood Pharma (IRWD)
Is Ironwood Pharmaceuticals, Inc. (IRWD) the Best Small Cap Pharma Stocks to Buy Now?
IRWD's Q4 Earnings and Revenues Fall Shy of Estimates, Stock Down
A Quick Look at Today's Ratings for Ironwood Pharmaceuticals(IRWD.US), With a Forecast Between $3 to $14
Q4 2024 Ironwood Pharmaceuticals Inc Earnings Call
Ironwood Pharmaceuticals' Earnings Call: Growth Amid Challenges
Earnings Call Summary | Ironwood Pharmaceuticals(IRWD.US) Q4 2024 Earnings Conference
IRONWOOD PHARMACEUTICALS Earnings Results: $IRWD Reports Quarterly Earnings
Ironwood Pharmaceuticals 2025 Outlook: Expects Revenue Of $260M–$290M Vs. $287.583M Est., Sees Adjusted EBITDA Above $85M
Ironwood Pharmaceuticals Ended 2024 With $88.6M of Cash and Cash Equivalents >IRWD
Ironwood Pharmaceuticals | 8-K: Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results; Achieves 2024 Financial Guidance
Express News | Ironwood Pharmaceuticals Inc - Outlook FY Total Revenue $260 - $290 Million